Trials / Completed
CompletedNCT03723811
Clinical Study to Investigate the Efficacy and Safety of SJP002 Ophthalmic Solution in Patients With Dry Eye Syndrome.
A Multicenter, Placebo Controlled, Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of SJP002 Eye Drops in Patients With Dry Eye Syndrome.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Samjin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy and safety of SJP002 ophthalmic solution compared to placebo in patients with Dry Eye Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SJP002 BID | 1 drop b.i.d for 12 weeks |
| DRUG | SJP002 QID | 1 drop q.i.d for 12 weeks |
| DRUG | SJP002 Placebo 1 | 1 drop q.i.d for 12 weeks |
| DRUG | SJP002 Placebo 2 | 1 drop q.i.d for 12 weeks |
Timeline
- Start date
- 2017-11-28
- Primary completion
- 2018-06-26
- Completion
- 2018-06-26
- First posted
- 2018-10-30
- Last updated
- 2022-04-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03723811. Inclusion in this directory is not an endorsement.